|Bid||42.50 x 1200|
|Ask||42.54 x 800|
|Day's Range||41.81 - 43.28|
|52 Week Range||22.57 - 51.76|
|Beta (5Y Monthly)||0.74|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 28, 2020 - Nov 02, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||55.63|
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, announced today that Andy Wade is stepping down from the position of Chief Financial Officer (CFO) for personal reasons and moving into an advisory role through March 5, 2021. Angie Wirick, current Vice President of Finance, has been promoted to CFO effective immediately.
We know that hedge funds generate strong, risk-adjusted returns over the long run, which is why imitating the picks that they are collectively bullish on can be a profitable strategy for retail investors. With billions of dollars in assets, professional investors have to conduct complex analyses, spend many resources and use tools that are not […]
AtriCure, Inc. (NASDAQ:ATRC) defied analyst predictions to release its second-quarter results, which were ahead of...